EurekAlert -- Two new clinical trials presented by Calpis Co., Ltd. at the American Society of Hypertension (ASH) Twenty-Third Annual Scientific Meeting and Exposition (ASH 2008) in New Orleans show that the milk-derived dietary supplement AmealPeptide® reduces blood pressure in hypertensive patients. The studies, called AHEAD (Achieve Hypertension Efficacy with AmealPeptide® Dietary Supplement ) II, and the PROBE (A Prospective, Two-phase Randomized, Open-Label, Blinded End-Point) Dose Response Study confirmed the safety and efficacy of AmealPeptide® for patients with Stage I and Stage II hypertension.
